P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro

  1. Helena S.Y. Mancebo1,
  2. Gary Lee1,
  3. John Flygare1,
  4. Joanne Tomassini3,
  5. Percy Luu1,
  6. Yuerong Zhu2,
  7. Junmin Peng2,
  8. Carol Blau3,
  9. Daria Hazuda3,
  10. David Price2, and
  11. Osvaldo Flores1,4
  1. 1Tularik, Inc., South San Francisco, California 94080 USA; 2Department of Biochemistry, University of Iowa, Iowa City, Iowa 52242 USA; 3Department of Antiviral Research, Merck Research Laboratories, West Point, Pennsylvania 19446 USA

Abstract

To identify novel inhibitors of transcriptional activation by the HIV Tat protein, we used a combination of in vitro and in vivo Tat-dependent transcription assays to screen >100,000 compounds. All compounds identified blocked Tat-dependent stimulation of transcriptional elongation. Analysis of a panel of structurally diverse inhibitors indicated that their target is the human homolog ofDrosophila positive transcription elongation factor b (P-TEFb). Loss of Tat transactivation in extracts depleted of the kinase subunit of human P-TEFb, PITALRE, was reversed by addition of partially purified human P-TEFb. Transfection experiments with wild-type or kinase knockout PITALRE demonstrated that P-TEFb is required for Tat function. Our results suggest that P-TEFb represents an attractive target for the development of novel HIV therapeutics.

Keywords

Footnotes

  • 4 Corresponding author.

  • E-MAIL Lalo{at}Tularik.com; FAX (415) 829-4400.

    • Received August 1, 1997.
    • Accepted August 22, 1997.
| Table of Contents

Life Science Alliance